VCRE (Vicore Pharma Holding AB) Cyclically Adjusted PB Ratio: (As of Aug. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $12.50
! 2 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB  (NAS:VCRE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Related Terms


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.36 1.89

Vicore Pharma Holding AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.24 2.20 1.89 1.70 2.16

VCRE vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.186/134.6100*134.6100
=3.186

Current CPI (Jun. 2026) = 134.6100.

Vicore Pharma Holding AB Quarterly Data

Book Value per Share CPI Adj_Book
201609 6.265 101.138 8.338
201612 2.369 102.022 3.126
201703 6.157 102.022 8.124
201706 7.524 102.752 9.857
201709 8.038 103.279 10.476
201712 3.694 103.793 4.791
201803 7.660 103.962 9.918
201806 7.486 104.875 9.609
201809 5.592 105.679 7.123
201812 9.330 105.912 11.858
201903 6.912 105.886 8.787
201906 6.192 106.742 7.809
201909 5.470 107.214 6.868
201912 6.611 107.766 8.258
202003 5.808 106.563 7.337
202006 5.653 107.498 7.079
202009 7.492 107.635 9.370
202012 6.826 108.296 8.485
202103 9.986 108.360 12.405
202106 9.030 108.928 11.159
202109 7.257 110.338 8.853
202112 5.718 112.486 6.843
202203 4.128 114.825 4.839
202206 3.078 118.384 3.500
202209 1.995 122.296 2.196
202212 3.311 126.365 3.527
202303 2.549 127.042 2.701
202306 2.998 129.407 3.119
202309 4.450 130.224 4.600
202312 3.866 131.912 3.945
202403 4.089 132.205 4.163
202406 3.612 132.716 3.664
202409 3.216 132.304 3.272
202412 4.383 132.987 4.436
202503 4.292 132.825 4.350
202506 4.055 133.699 4.083
202509 3.632 133.480 3.663
202512 4.187 133.390 4.225
202603 3.778 133.560 3.808
202606 3.186 134.610 3.186

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB Business Description

Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.50
Price